Healthequity, Inc. (HQY) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 16, 2026
Summary
Healthequity’s revenue went from $178M in fiscal 2017 to $1.3B in fiscal 2026, growth of about 24.8% a year.
Net income in fiscal 2026 was $215M, a net margin of 16.4%; the highest of the period.
Over the twelve months to July 31, 2026, revenue was $1.4B and net income $236M.
Free cash flow was $455M in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count rose 46% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1000M | $862M | $757M | $734M | $532M | $287M | $230M | $178M |
| Gross profit | $970M | $913M | $777M | $623M | $492M | $425M | $415M | $326M | $181M | $135M | $106M |
| Operating income | $351M | $322M | $162M | $118M | $9M | -$24M | $34M | $77M | $78M | $54M | $41M |
| Net income | $236M | $215M | $97M | $56M | -$26M | -$44M | $9M | $40M | $74M | $47M | $26M |
| EPS (diluted) | $2.77 | $2.46 | $1.09 | $0.64 | $-0.31 | $-0.53 | $0.12 | $0.58 | $1.17 | $0.77 | $0.44 |
| R&D | $278M | $263M | $240M | $219M | $193M | $157M | $125M | $78M | $35M | $27M | $22M |
| Revenue growth | — | +9.5% | +20.0% | +16.0% | +13.9% | +3.1% | +37.9% | +85.2% | +25.1% | +28.7% | +40.7% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $490M | $457M | $340M | $243M | $151M | $141M | $182M | $105M | $113M | $82M | $46M |
| Capital spending | -$2M | -$2M | -$2M | -$2M | -$3M | -$9M | -$13M | -$7M | -$4M | -$5M | -$4M |
| Free cash flow | $488M | $455M | $338M | $241M | $147M | $132M | $169M | $98M | $110M | $76M | $42M |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | $0 |
| Buybacks | $404M | $299M | $121M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $81M | $73M | $96M | $77M | $63M | $53M | $43M | $40M | $21M | $14M | $8M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $319M | $296M | $404M | $254M | $225M | $329M | $192M | $361M | $199M | $140M |
| Debt | — | $1.0B | $1.1B | $933M | $994M | $1.0B | $1.1B | $1.3B | $0 | — | — |
| Equity | — | $2.1B | $2.1B | $2.0B | $1.9B | $1.9B | $1.4B | $1.0B | $477M | $346M | $262M |
| Total assets | — | $3.4B | $3.4B | $3.2B | $3.1B | $3.1B | $2.7B | $2.6B | $510M | $369M | $279M |
| Shares (diluted) | 84M | 87M | 89M | 87M | 84M | 83M | 76M | 68M | 63M | 62M | 60M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 71.2% | 69.5% | 64.8% | 62.3% | 57.1% | 56.1% | 56.6% | 61.3% | 63.1% | 58.8% | 59.6% |
| Operating margin | 25.8% | 24.6% | 13.5% | 11.8% | 1.1% | -3.2% | 4.6% | 14.5% | 27.0% | 23.7% | 23.1% |
| Net margin | 17.4% | 16.4% | 8.1% | 5.6% | -3.0% | -5.9% | 1.2% | 7.5% | 25.7% | 20.6% | 14.8% |
| FCF margin | 35.8% | 34.6% | 28.1% | 24.1% | 17.1% | 17.5% | 23.0% | 18.4% | 38.1% | 33.2% | 23.5% |
| ROIC | — | 8.1% | 4.2% | 2.9% | 0.2% | -0.6% | 1.1% | 3.0% | 15.9% | 14.3% | 10.3% |
| ROE | — | 10.2% | 4.6% | 2.7% | -1.4% | -2.4% | 0.6% | 3.9% | 15.5% | 13.7% | 10.1% |
Frequently asked questions
What is Healthequity’s annual revenue?
$1.3B in fiscal 2026 and $1.4B over the twelve months to July 31, 2026.
How much profit does Healthequity make?
Net income was $215M in fiscal 2026 (net margin 16.4%).
Is Healthequity’s revenue growing?
Yes: revenue rose 9.5% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.